ArticleEuropean heart journal open2026
Hospital-treated infectious diseases and polygenic susceptibility in relation to heart failure and cardiac remodelling: evidence from the UK Biobank and ARIC cohorts.
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Infectious diseases (IDs) are increasingly recognized as precipitants of heart failure (HF). However, the impact of diverse pathogens and genetic susceptibility on HF and cardiac remodelling remains unclear. Methods and results: We analysed 480 154 UK Biobank (UKB) participants and 9816 Atherosclerosis Risk in Communities (ARIC) participants free of HF at baseline. Hospital-treated IDs were ascertained with 931 ICD-10 codes and modelled as time-varying exposures. Incident HF and HF with preserved (HFpEF) and reduced ejection fraction (HFrEF) were identified through hospital records and adjudication. Polygenic risk scores (PRSs) for ID-overall and pathway-specific for TGF-β, acute inflammation, and myocardial fibrosis-were derived from genome-wide association study data. Multivariable Cox and Fine-Gray models estimated hazard ratios (HRs); cardiac structure and function were assessed by cardiac MRI in UKB and echocardiography in ARIC. Over median follow-up of 13.5 years (UKB) and 22.4 years (ARIC), any hospital-treated ID was associated with higher HF risk (UKB HR 1.54, 95% CI 1.46-1.63; ARIC HR 1.84, 1.68-2.00). Risks were similar for bacterial, viral, fungal, and parasitic infections, peaked within 180 days (HR 5.88), and persisted >1 year. Infectious diseases increased both HFpEF (sub-HR 1.81) and HFrEF (2.03). Imaging revealed higher left-ventricular mass, wall thickness, mass-to-volume ratio and filling pressures, and lower ejection fraction among infected individuals. In infection-free participants, higher overall ID-PRS predicted incident HF (per-SD HR 1.07 UKB; 1.11 ARIC) and adverse cardiac remodelling, with strongest effects for TGF-β and acute-inflammation pathways. Conclusion: Hospital-treated IDs and genetic predisposition to infection are independently associated with HF and adverse cardiac phenotypes. Integrating infection history and ID-PRS may enhance HF risk stratification and motivate trials targeting fibro-inflammatory pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.